Compare Franklin Resources, Inc. (BEN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin Resources, Inc. vs Sanofi SA — how do they compare? Franklin Resources, Inc. trades at $33.37 (market cap $16.95B), while Sanofi SA trades at $43.51 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 6.2× Franklin Resources, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| BEN | SNY | |
|---|---|---|
Market Cap | $16.95B | $104.30B |
Sector | Financials | Health |
52-Week High | $35.77 | $52.34 |
52-Week Low | $21.18 | $41.33 |
Enterprise Value | $29.90B | $124.19B |
Dividend Yield | 3.96% | 5.55% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
